Current through Register Vol. 61, No. 4, April 1, 2022
Treatment Services: The Opioid Treatment Program shall provide patients the
following services and activities and document the time or manner of each
service or activity in the patient record:
Dispensing of approved opioid agonist medications;
(b) Individual group, or family counseling,
as clinically indicated;
Information and training in parenting skills;
(d) HIV, AIDS, tuberculosis, sexually
transmitted diseases, and other infectious disease information;
(e) Completion of HIV, TB, STD risk
assessment within 30 days of admission;
(f) Relapse prevention training;
For pregnant patients in a
treatment program who were not admitted under OAR 415-020-0025
(5), a treatment
program shall give them the opportunity for prenatal care. If a program cannot
provide direct prenatal care for pregnant patients in treatment, it shall
establish a system of referring them for prenatal care, which may be either
publicly or privately funded. If there is no publicly funded prenatal care
available to which a patient may be referred, and the program cannot provide
such services, or the patient cannot afford or refuses prenatal care services,
then the treatment program shall, at a minimum, offer her basic prenatal
instruction on maternal, physical, and dietary care as a part of its counseling
Resources: The program, to the extent of community resources available and as
clinically indicated, shall provide patients with information and referral to
the following services:
(a) Self help groups
and other support groups;
Recreational programs and activities;
(d) Prevocational, occupational, and
(g) Smoking cessation
assistance counseling programs.
Crisis intervention; and
Comprehensive drug education.
(3) Non-compliance: Patients who are
non-compliant with program rules may be discharged following medically
supervised withdrawal. Clinical justification for medically supervised
withdrawal schedules of less than 21 days must be documented in the patient
record. For discharges because of failure to pay fees, detoxification periods
of less than 21 days are not permitted.
Testing for Drug Use: The program shall
use observed urine drug screening as an aid in monitoring and evaluating a
patient's progress in treatment. The urine drug screening shall include;
(a) A sensitive, rapid, and inexpensive
immunoassay screen to eliminate "true negative" specimens; and
(b) If the initial test is positive, a
confirmatory test, which is a second analytical procedure used to identify the
presence of a specific drug or metabolite in a urine specimen. The confirmatory
test must be conducted by a different analytical method from that of the
initial test, to ensure reliability and accuracy.
Standards for Urine Tests: All urine
tests shall be performed by laboratories meeting the licensing standards of OAR
(6) All urine tests shall, at a minimum,
screen for synthetic opiates, opiates, amphetamines, cocaine, benzodiazepines,
(7) Frequency of urine
testing: The Opioid Treatment Program must provide adequate testing or analysis
for drugs of abuse, including at least eight random drug abuse tests per year,
for each patient in maintenance treatment, in accordance with generally
accepted clinical practice. More frequent drug testing shall be done if
clinically indicated. The program shall document in the patient record the
results of any tests and interventions made by the program to address those
tests which are positive for illicit substances.
Or. Admin. R.
HR 4-1988, f. & cert.
ef. 5-10-88; HR 17-1993, f. & cert. ef. 7-23-93, Renumbered from
410-006-0040; ADAP 3-1995, f. 12-1-95, cert. ef. 3-1-96; ADS 1-2003, f.
6-13-03, cert. ef. 7-1-03; ADS 2-2008, f. & cert. ef.
Stat. Auth.: ORS
Stats. Implemented: ORS
& 430.560 -